ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2021

Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer.

Aditya Bardia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.